A Diosynth room with a ThromboView

Published: 11-Aug-2005

Agenix - a global health and biotechnology company based in Brisbane, Australia - has signed a contract with Diosynth Biotechnology - a division of Organon, the human healthcare business unit of Akzo Nobel, that supplies contract manufacturing services for the global biotechnology industry - to begin the process of manufacturing ThromboView, it's lead candidate, for Phase III clinical trials and commercial sale, with a view to providing cGMP material for the trials by the third quarter of 2006.


Agenix - a global health and biotechnology company based in Brisbane, Australia - has signed a contract with Diosynth Biotechnology - a division of Organon, the human healthcare business unit of Akzo Nobel, that supplies contract manufacturing services for the global biotechnology industry - to begin the process of manufacturing ThromboView, it's lead candidate, for Phase III clinical trials and commercial sale, with a view to providing cGMP material for the trials by the third quarter of 2006.

The process development and manufacturing agreement will see Agenix transfer the manufacturing process developed by the company to the Research Triangle Park facility of Diosynth Biotechnology for further process refinement and cGMP manufacturing.

ThromboView is blood clot-imaging project that uses radiolabelled antibodies to locate blood clots in the body. It is being developed with the assistance of the Federal Government through its START scheme. Agenix plans to conclude a sales, marketing and distribution agreement by the end of this year.

Over the past twelve months, working in conjunction with a team from ExcellGene, Monthey, Switzerland, Agenix has been able to increase the productivity of the cell line ten-fold, resulting in smaller scale commercial manufacture and significant economic benefits.

'This is a very important milestone in the ThromboView programme,' said Agenix md Donald Home. 'Given the promising results we have seen from the completed clinical trials we remain confident in both the clinical need and performance for this product. With this manufacturing transfer we will be able to continue to drive the clinical development and deliver as per our timeline.'

You may also like